Njection, the features of astroglial activation (enlarged cell bodies and thick

Njection, the features of astroglial NT-157 activation (enlarged cell bodies and thick processes) in the SN and CPu were observed more frequently in wild-type mice compared to ATF6a 2/2 mice (Fig. 3 A I, II, 2nd and 3rd rows). In the wild-type SN, astrocytes became enlarged in the SN pars reticulata (SNpr) first (arrowheads), and then penetrated into the SNpc 25033180 (asterisks), but ATF6a 2/2 astrocytes were not enlarged after MPTP/P injections. In the CPu, wild-type astrocytes near the lateral ventricle (arrows) and corpus callosum (data not shown) became enlarged and, almost simultaneously, spread over the CPu, but again, ATF6a 2/2 astrocytes were not enlarged after MPTP/P injections. Consistent with the immunohistochemical observations, Western blot analyses revealed enhanced GFAP expression in wild-type mice, but not in ATF6a 2/2 mice, after the 2nd and 3rd MPTP/P injections (Fig.4 C I). In contrast to high levels of astroglial activation, microglial activation was modest in this model, and the differences in the microglia morphology were not clear between wild-type and ATF6a 2/2 mice after the 2nd MPTP/P injection (Fig. 3 A II). Activated astrocytes contribute to neuroprotection in several ways, including neurotrophic factor synthesis, enhancement of anti-oxidative systems, and glutamate metabolism [16,17]. Therefore, we compared the expression of BDNF (a neurotrophic factor), HO-1 (an anti-oxidative gene), and GLT-1 (a glutamate transporter) in wild-type and ATF6a 2/2 mice. Immunohistochemical analyses revealed that BDNF and HO-1 expression (Fig. 3 B I, II), but not GLT-1 expression (Fig. S2 C), were higher after MPTP/P injections in wild-type astrocytes compared with ATF6a 2/2 astrocytes in the CPu.Accelerated Neurodegeneration and Ub Accumulation in ATF6a 2/2 Mice after MPTP/P InjectionsTo evaluate the neuroprotective role of the UPR in the chronic MPTP/P injection model, we immunehistochemically compared nigrostriatal neuronal degeneration between wild-type and ATF6a 2/2 mice (Fig. 2 A I, II). In the control condition (without MPTP/P administration), the number of TH-positive neurons in the SNpc and the intensity of TH in the CPu were not significantly different among the wild-type and ATF6a-deficient mice. In contrast, in the early course of MPTP/P injections (2nd and 3rd injections), the number of TH-positive neurons in the SNpc and the intensity of TH in the CPu were significantly lower in ATF6a 2/2 mice compared to wild-type mice. Consistent with these results, higher numbers of activated caspase-3-positive, THpositive neurons were observed in ATF6a 2/2 mice (74 ) compared to wild-type mice (47 ; Fig. 2 A III). The specificity of the antibody and the appropriate immunoreactivity of the antigen were confirmed by the negative control experiment where primary antibody was omitted (Fig. S 2 A) and the serial photograph of the confocal images (Fig. S 2 B), respectively. In the later injections (6th?0th injections), however, the nigrostriatal dopaminergic neurons had degenerated to similar levels in both cohorts (Fig.2 A I, II). Egawa et al. recently demonstrated the presence of MedChemExpress 60940-34-3 Ubpositive inclusions in ATF6a 2/2 mice after acute MPTP injection [12]. Therefore, we assessed Ub accumulation in our model. In the control condition, slight Ub immunoreactivity in theReduced UPR Levels and Gene Expression in ATF6a 2/2 Astrocytes after MPTP/P InjectionsTo determine whether impaired astroglial activation was associated with reduced UPR levels in ATF6a.Njection, the features of astroglial activation (enlarged cell bodies and thick processes) in the SN and CPu were observed more frequently in wild-type mice compared to ATF6a 2/2 mice (Fig. 3 A I, II, 2nd and 3rd rows). In the wild-type SN, astrocytes became enlarged in the SN pars reticulata (SNpr) first (arrowheads), and then penetrated into the SNpc 25033180 (asterisks), but ATF6a 2/2 astrocytes were not enlarged after MPTP/P injections. In the CPu, wild-type astrocytes near the lateral ventricle (arrows) and corpus callosum (data not shown) became enlarged and, almost simultaneously, spread over the CPu, but again, ATF6a 2/2 astrocytes were not enlarged after MPTP/P injections. Consistent with the immunohistochemical observations, Western blot analyses revealed enhanced GFAP expression in wild-type mice, but not in ATF6a 2/2 mice, after the 2nd and 3rd MPTP/P injections (Fig.4 C I). In contrast to high levels of astroglial activation, microglial activation was modest in this model, and the differences in the microglia morphology were not clear between wild-type and ATF6a 2/2 mice after the 2nd MPTP/P injection (Fig. 3 A II). Activated astrocytes contribute to neuroprotection in several ways, including neurotrophic factor synthesis, enhancement of anti-oxidative systems, and glutamate metabolism [16,17]. Therefore, we compared the expression of BDNF (a neurotrophic factor), HO-1 (an anti-oxidative gene), and GLT-1 (a glutamate transporter) in wild-type and ATF6a 2/2 mice. Immunohistochemical analyses revealed that BDNF and HO-1 expression (Fig. 3 B I, II), but not GLT-1 expression (Fig. S2 C), were higher after MPTP/P injections in wild-type astrocytes compared with ATF6a 2/2 astrocytes in the CPu.Accelerated Neurodegeneration and Ub Accumulation in ATF6a 2/2 Mice after MPTP/P InjectionsTo evaluate the neuroprotective role of the UPR in the chronic MPTP/P injection model, we immunehistochemically compared nigrostriatal neuronal degeneration between wild-type and ATF6a 2/2 mice (Fig. 2 A I, II). In the control condition (without MPTP/P administration), the number of TH-positive neurons in the SNpc and the intensity of TH in the CPu were not significantly different among the wild-type and ATF6a-deficient mice. In contrast, in the early course of MPTP/P injections (2nd and 3rd injections), the number of TH-positive neurons in the SNpc and the intensity of TH in the CPu were significantly lower in ATF6a 2/2 mice compared to wild-type mice. Consistent with these results, higher numbers of activated caspase-3-positive, THpositive neurons were observed in ATF6a 2/2 mice (74 ) compared to wild-type mice (47 ; Fig. 2 A III). The specificity of the antibody and the appropriate immunoreactivity of the antigen were confirmed by the negative control experiment where primary antibody was omitted (Fig. S 2 A) and the serial photograph of the confocal images (Fig. S 2 B), respectively. In the later injections (6th?0th injections), however, the nigrostriatal dopaminergic neurons had degenerated to similar levels in both cohorts (Fig.2 A I, II). Egawa et al. recently demonstrated the presence of Ubpositive inclusions in ATF6a 2/2 mice after acute MPTP injection [12]. Therefore, we assessed Ub accumulation in our model. In the control condition, slight Ub immunoreactivity in theReduced UPR Levels and Gene Expression in ATF6a 2/2 Astrocytes after MPTP/P InjectionsTo determine whether impaired astroglial activation was associated with reduced UPR levels in ATF6a.